Up to 85 percent of all lung cancer cases are characterized as non-small cell lung cancer, underscoring the importance of keeping up to date on the latest diagnostic and treatment advances. That’s why this Spotlight on Non-Small Cell Lung Cancer brings together leading oncologists and other allied healthcare professionals to discuss key research updates and other novel insights.
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
NSCLC Care: Evaluating Durvalumab in the First-Line Setting
NSCLC Care: Evaluating Durvalumab in the First-Line Setting
The Evolving Landscape of Targeted Therapies for Non-Small Cell Lung Cancer
The Evolving Landscape of Targeted Therapies for Non-Small Cell Lung Cancer
Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Challenging the Standard of Care in NSCLC: Findings from the TROPION-Lung01 Study
Challenging the Standard of Care in NSCLC: Findings from the TROPION-Lung01 Study
Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
Recognizing the Role of Capmatinib for METex14 in NSCLC
Recognizing the Role of Capmatinib for METex14 in NSCLC
Checkpoint Inhibitor Combination Therapy for First-Line Advanced NSCLC
Checkpoint Inhibitor Combination Therapy for First-Line Advanced NSCLC
Investigating Immunotherapy & Its Role in NSCLC
Investigating Immunotherapy & Its Role in NSCLC
Concerning Kinases: Therapeutic Considerations for RET Rearranged NSCLC
Concerning Kinases: Therapeutic Considerations for RET Rearranged NSCLC
